Difficulties in the revaccination program of hematopoietic stem cell transplantation recipients
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
SILVA, Paula Moreira da
SILVA, Elen Monteiro da
SIMIONI, Anderson Joao
SOUZA, Mair Pedro de
COLTURATO, Vergilio Antonio Rensi
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.59, article ID UNSP e69, 9p, 2017
Resumo
Hematopoietic stem cell transplant (HSCT) recipients should be routinely revaccinated after transplantation. We evaluated the difficulties met in the revaccination program and how a prospective and tailored follow-up could help to overcome these obstacles. HSCT recipients (n=122) were prospectively followed up and categorized into Group 1 (n=72), recipients who had already started the revaccination program, and Group 2 (n=50), recipients starting their vaccines. Whenever a difficulty was reported, interventions and subsequent evaluations were performed. Reported problems were related to patient compliance, HSCT center and/or vaccination center. Problems related to patient compliance were less frequent than those related to HSCT center modifications of previous recommendations, or to errors made by the vaccination center. The main gap found was vaccination delays (81.9%). Advisory intervention was needed in 64% and 46% of Group 1 and Group 2, respectively (p=0.05), and was partially successful in around 70% of the cases. Total resolution was achieved in more than 35% in both groups. Improvements are needed in the Brazilian vaccination program for HSCT recipients to assure a complete and updated revaccination schedule. HSCT centers should assign nurses and transplant infectious disease specialist physicians to organize the revaccination schedule and to monitor the program development.
Palavras-chave
Hematopoietic stem cell transplantation, Immunization, Difficulties in revaccination
Referências
- Ariza-Heredia EJ, 2014, TRANSPL INFECT DIS, V16, P878, DOI 10.1111/tid.12312
- Brasil. Ministero da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2014, MAN CTR REF IM ESP
- Cordonnier C, 2015, CLIN INFECT DIS, V61, P313, DOI 10.1093/cid/civ287
- Cordonnier C, 2009, CLIN INFECT DIS, V48, P1392, DOI 10.1086/598324
- de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142
- Hilgendorf Inken, 2011, Vaccine, V29, P2825, DOI 10.1016/j.vaccine.2011.02.018
- Hudspeth MP, 2010, PEDIATR BLOOD CANCER, V54, P970, DOI 10.1002/pbc.22444
- [Anonymous], 2016, VAC PNEUM 10 VAL CON
- Johnston B Lynn, 2002, Can J Infect Dis, V13, P353
- Klok RM, 2013, CLIN THER, V35, P119, DOI 10.1016/j.clinthera.2012.12.006
- Lee DG, 2013, INFECT CHEMOTHER, V45, P272, DOI 10.3947/ic.2013.45.3.272
- Lerchenfeldt SM, 2013, TRANSPL INFECT DIS, V15, P634, DOI 10.1111/tid.12110
- Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870
- LJUNGMAN P, 1994, BLOOD, V84, P657
- Ljungman P, 2004, BONE MARROW TRANSPL, V34, P589, DOI 10.1038/sj.bmt.1704634
- Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
- Ljungman P, 2010, BIOL BLOOD MARROW TR, V16, P1608, DOI 10.1016/j.bbmt.2010.08.009
- Machado CM, 2005, EXPERT REV VACCINES, V4, P219, DOI 10.1586/14760584.4.2.219
- Machado CM, 2004, BRAZ J MED BIOL RES, V37, P151, DOI 10.1590/S0100-879X2004000100021
- Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
- Molina A. C., 2007, Acta Scientiarum - Health Science, V29, P99
- Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332
- Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641
- Prager J, 1992, Kinderarztl Prax, V60, P195
- Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
- Santos AC, 2009, BONE MARROW TRANS S1, V43, pS63
- Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019